Biotechnology

BiomX

BiomX released FY2025 Q3 earnings on November 12 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -5.5463 (forecast USD -6.08)

BiomX released FY2025 9 Months Earnings on November 12 Pre-Market (EST), with actual revenue of USD 0 and EPS of USD -0.8162

BiomX to Release FY2025 Q3 Earnings on November 12 Pre-Market EST, Forecast EPS -0.32 USD

BiomX Inc. Receives Additional FDA Questions on BX004 Inhaler Device

BIOMX Provides BX004 Project Update and Receives Positive FDA Feedback

BiomX released FY2025 Q2 earnings on August 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1928 (forecast USD -0.26)

BiomX released FY2025 Semi-Annual Earnings on August 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.5494 (forecast USD -12.54)

BiomX to Release FY2025 Q2 Earnings on August 13 Pre-Market EST, Forecast Revenue USD 0, EPS USD -0.26

BiomX's BX004 clinical trial shows positive results

BiomX's Phage Therapy Platform Shows Early Results in Clinical Trials

BiomX Reports Positive Clinical Trial Progress for Phage Therapy

BiomX Inc. CEO to speak at Israel BioMed Conference

BiomX Inc. Q1 2025 Earnings Beat Expectations

HC Wainwright Maintains Buy Rating on BiomX and Adjusts Target Price

BiomX released FY2025 Q1 earnings on May 15 During-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -6.2987 (forecast USD -6.84)

BiomX Announces Positive Top-Line Results for BX211 Phase 2 Trial for Diabetic Foot Osteomyelitis

BiomX to release FY2025 Q1 earnings report on May 15 During-Market EST, forecast EPS USD -0.36

BiomX Inc. Announces Compliance with NYSE Audit Opinion Disclosure Guidelines

BiomX Inc. Announces Positive Trial Results for BX211 Treatment of Diabetic Foot Osteomyelitis

BiomX released FY2024 Q4 earnings on March 25 During-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -16.8485 (forecast USD -5.7)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap